Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference

Wednesday, October 8, 2008 General News J E 4
PT. RICHMOND, Calif., Oct. 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical company, announced today thatThomas P. Soloway, Senior Vice President and Chief Financial Officer, isscheduled to present at the Natixis Bleichroeder Second Annual Hidden GemsConference in New York City on Monday, October 13, 2008 at 9:30 AM EasternTime.

An audio webcast of the presentation will be available at and on the Transcept website at The replay of the presentation will be availablefor 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused onthe development and commercialization of proprietary products that addressimportant therapeutic needs in the fields of psychiatry and sleep medicine.The lead Transcept product candidate, Intermezzo(R), is a sublingual low doseformulation of zolpidem that has been developed for use as-needed for thetreatment of insomnia when a middle of the night awakening is followed bydifficulty returning to sleep. Phase 3 clinical trials have been completedfor Intermezzo(R) and, on September 30, 2008, Transcept submitted a New DrugApplication to the U.S. Food and Drug Administration.For further information, please visit the company's website at:

Safe Harbor

This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). Transceptdisclaims any intent or obligation to update these forward-looking statements,and claim the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are not limitedto, the expected benefits of Transcept product candidates. Such statements arebased on management's current expectations, but actual results may differmaterially due to various risks and uncertainties, including, but not limitedto, Transcept product candidates may have unexpected adverse side effects orinadequate therapeutic efficacy; positive results in clinical trials may notbe sufficient to obtain FDA approval; physician or patient reluctance to useIntermezzo(R), if approved; potential alternative therapies; maintainingadequate patent or trade secret protection without violating the intellectualproperty rights of others; and other difficulties or delays in, clinicaldevelopment, obtaining regulatory approval, market acceptance andcommercialization of Transcept product candidates.Transcept Pharmaceuticals, Inc. Michael Gill Director of Communications (510) 215-3575 The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025

SOURCE Transcept Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
GenVault Corporation Launches GenTegra(TM) DNA
Purina(R) Cat Chow(R) Brand Cat Food Partners With...